Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

• Insiders have been consistently selling shares, with 24 sales and no purchases in the past six months, including recent transactions by executives such as VP Daniel Lippis and SVP Andrew M. Dahl, which may signal a lack of confidence in the stock's near-term performance.
• Several institutional investors, including Ninety One UK Ltd and Ninety One North America Inc., have reduced their positions in Edwards Lifesciences Co. during the third quarter, with Ninety One UK Ltd selling 393,827 shares and Ninety One North America Inc. decreasing its stake by 5.6%, indicating potential institutional skepticism.
• The stock's price-to-earnings ratio of 30.76 is relatively high compared to some peers, which may limit upside potential if earnings growth does not accelerate to justify the valuation, especially given the company's guidance for FY 2026 EPS of $2.950 to $3.050.
• Short interest in Edwards Lifesciences Co. has increased slightly, with 9,538,735 shares shorted as of September 30, 2026, representing a 4.96% month-to-month increase, which could indicate bearish sentiment among some market participants.
• The company's dividend yield is 0.00%, meaning it does not provide income to investors, which may be a drawback for those seeking regular cash flow from their investments, particularly in a market where dividend-paying stocks are often favored for stability.